TNGX
Tango Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
consensus rating "Strong Buy"
EPS Beats Expectation
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About TNGX
Tango Therapeutics Inc.
A precision oncology company that develops therapeutic novel medicines targeting cancer vulnerbilities
201 Brookline Ave., Suite 901, Boston, MA 02215
--
Tango Therapeutics Inc., incorporated in Delaware on May 21, 2020, is a biotechnology company dedicated to discovering new drug targets and delivering next-generation precision medicine for the treatment of cancer. Tango uses a patient-starting and endpoint approach to discover and develop therapies for key cancer targets using the genetic principle of synthetic lethality. This includes expanding the scope of precise oncology targets into new areas, such as tumor suppressor gene loss and its contribution to the ability of cancer cells to evade immune cell killing.
Company Financials
EPS
TNGX has released its 2025 Q1 earnings. EPS was reported at -0.36, versus the expected -0.35, missing expectations. The chart below visualizes how TNGX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TNGX has released its 2025 Q1 earnings report, with revenue of 5.39M, reflecting a YoY change of -16.67%, and net profit of -39.88M, showing a YoY change of -5.17%. The Sankey diagram below clearly presents TNGX’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
